Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center

The Journal of Dermatological Treatment
Ayelet OllechDan Ben-Amitai

Abstract

There is a paucity of data on the use of biologic therapy in recalcitrant pediatric psoriasis. The current study presents pediatric psoriasis cases treated with biologic agents in a tertiary referral center. In this retrospective case series, data were collected on all patients ≤18 years old with severe psoriasis treated with biological therapy from 2010 through 2016 in a tertiary children's hospital. We included demographic data, previous systemic treatments, reason for discontinuation or switch to other systemic treatments, efficacy and side effects. There were 10 patients, mean age 5.75 (±3.3) years treated with biologic agents in our center; Etanercept was the most frequent biological treatment prescribed (n = 9) followed by adalimumab (n = 5) ustekinumab (n = 3) and infliximab (n = 2). Additional systemic therapy was added to the biological therapy in seven cases: Methotreaxate (n = 5), phototherapy (n = 4), cyclosporine A and colchicine (1 case each). The most common reason for discontinuation was secondary failure (5 for etanercept, 3 for adalimumab). Six patients failed one biological treatment and three patients failed two biological treatments. Four patients are still being treated with a first line biologic (Etanerce...Continue Reading

References

Feb 12, 2004·Pediatric Dermatology·M Alan Menter, John M Cush
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Jan 18, 2008·The New England Journal of Medicine·Amy S PallerUNKNOWN Etanercept Pediatric Psoriasis Study Group
Nov 20, 2009·The British Journal of Dermatology·M AugustinI Schäfer
Dec 8, 2009·Journal of the American Academy of Dermatology·Megha M TollefsonHilal Maradit Kremers
Jul 8, 2010·Journal of the American Academy of Dermatology·Amy S PallerGreg Kricorian
Jan 17, 2012·Journal of the American Academy of Dermatology·Alexa B KimballParvez M Mulani
Apr 6, 2013·Dermatologic Clinics·Ann L Marqueling, Kelly M Cordoro
May 17, 2013·American Journal of Clinical Dermatology·Kara N Shah
Mar 3, 2015·Pediatric Dermatology·Fernanda Bellodi Schmidt, Kara N Shah
Feb 13, 2016·Pediatric Dermatology·Daniel M KlufasBruce E Strober
Mar 2, 2016·The British Journal of Dermatology·E Burden-TehR Murphy
May 18, 2017·JAMA Dermatology·Emily OsierLawrence F Eichenfield

❮ Previous
Next ❯

Citations

Sep 14, 2019·Children·Abigail ClineSteven R Feldman
Feb 6, 2020·Paediatric Drugs·Yi-Wei Huang, Tsen-Fang Tsai
Apr 1, 2021·Expert Review of Clinical Pharmacology·Emmanuel MahéCéline Phan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.